Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 07, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
February 26, 2025 10:45 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
February 05, 2025 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Glioblastoma Market, an Area With High Trial Failure And Unmet Need is Expected to Witness Significant Growth Owing to Increased Usage of Bevacizumab, Temozolimide, Optune Gio Along with Emergence of New Class of Therapies | DelveInsight
January 27, 2025 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Glioblastoma Market, an Area With High Trial Failure And Unmet Need is Expected to Witness Significant Growth Owing to Increased Usage of...
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
January 21, 2025 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Ivy Brain Tumor Center Expands Global Phase 3 Gliofocus Study to the EU and Additional U.S. States
January 15, 2025 09:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gliofocus Study is now open in Paris and Madrid. The global Gliofocus network includes 68 EU medical centers. In the United States, The...
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries
January 09, 2025 10:53 ET
|
Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "NUT Midline Carcinoma Treatment Market by Treatment, by Route of Administration, by End-User, and By Region" report has been added to ...
invIOs to present progress across oncology pipeline during JP Morgan Week 2025
December 16, 2024 09:00 ET
|
invIOs GmbH
VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
November 26, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...